Jarno Hoekman
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Gaining regulatory acceptance for novel technologies in nonclinical drug development: A scoping review of its conceptualization in scientific literature.
Journal: Drug discovery today
Published: October 14, 2025
Pursuing societal impact in research projects on NAM development: An analysis of routes to impact.
Journal: NAM journal
Published: July 30, 2025
Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study.
Journal: BMJ open
Published: November 09, 2024
Development of the fish invitrome for animal-free environmental risk assessment of chemicals.
Journal: Environmental toxicology and chemistry
Published: September 07, 2024
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data.
Journal: ALTEX
Published: July 21, 2024
Animal-free safety assessment of chemicals: an innovation system perspective.
Journal: Archives of toxicology
Published: July 19, 2024
Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role.
Journal: Drug discovery today
Published: July 03, 2024
Four scenarios for the future of medicines and social policy in 2030.
Journal: Drug discovery today
Published: November 22, 2021
Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks.
Journal: Expert opinion on drug safety
Published: July 15, 2021
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: March 26, 2021
Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs.
Journal: British journal of clinical pharmacology
Published: March 03, 2021
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Journal: Clinical and translational science
Published: December 23, 2020
Last Updated: 09/26/2026